Predicting Chemotherapy Response to Paclitaxel-Based Therapy in Advanced Non-Small-Cell Lung Cancer with P-Glycoprotein Expression

Respiration ◽  
2003 ◽  
Vol 70 (1) ◽  
pp. 32-35 ◽  
Author(s):  
J.J. Yeh ◽  
W.H. Hsu ◽  
J.J. Wang ◽  
S.T. Ho ◽  
A. Kao
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Chemotherapy Response ◽  
Small Cell Lung ◽  
P Glycoprotein

Phase II study of docetaxel and S-1 combination therapy in patients with previously treated non-small cell lung cancer

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 18122-18122
Author(s):  
S. Atagi ◽  
M. Kawahara ◽  
A. Kubo ◽  
T. Kawaguchi ◽  
K. Yumine ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Controlled Trial ◽  
Small Cell ◽  
Stage Iiib ◽  
Chemotherapy Response ◽  
Small Cell Lung ◽  
Platinum Based Chemotherapy ◽  
Previously Treated

18122 Background: Docetaxel is active against chemotherapy-pretreated non-small-cell lung cancer (NSCLC). S-1 is a novel oral fluoropyrimidine, composed of tegafur, 5-chloro-2,4-dihydroxypyridine (dihydropyrimidinedehydrogenase inhibitor), and potassium oxonate (orotate phosphoribosyl transferase inhibitor). It has been commercially available and used for NSCLC in Japan. We conducted this study to evaluate the efficacy and safety of docetaxel combined with S-1 in NSCLC patients (pts) who were previously treated with one or more regimens. Methods: Eligible pts were required to have histologically or cytologically confirmed measurable or evaluable stage IIIB or IV NSCLC, age= 20 years, one or more previous chemotherapy, a performance status (PS) 0–1, and adequate organ function and bone marrow reserve. In this study, pts received S-1 (80 mg/m2 orally on days 1–14) and docetaxel (40mg/m2 IV on days 1). Treatment was repeated every 3 weeks. Results: Between January 2005 and May 2006, 30 pts were enrolled on this study. 29 pts were eligible and evaluable. Median age was 67 (48–79), male/female (23/6), PS 0/1 (9/20), stage IIIB/IV (7/22), and prior chemotherapy regimen 1/2/3 (23/4/2). 28 pts received a platinum-based chemotherapy. Response: PR=7(24%), SD=13, PD=7, NE=2. Median survival time was 10.2 months. Grade 3/4 toxicities (% of pts) were as follows: leukocytes 6/0 (20.6%), neutrophils 7/3 (34.4%), platelets 0/0, infection 0/1 (3.4%), fever 2/0 (6.9%), diarrhea 1/0 (3.4%), neurology 0/1 (3.4%), and mucositis 1/0 (3.4%). There were no treatment-related deaths. Conclusions: The combination of docetaxel and S-1 was effective with acceptable toxicity in pts with previously treated NSCLC. These results warrant further investigations of this regimen a randomized controlled trial as a second-line treatment for NSCLC. No significant financial relationships to disclose.

Predicting Chemotherapy Response to Paclitaxel-Based Therapy in Advanced Non-Small-Cell Lung Cancer (Stage IIIb or IV) with a Higher T Stage (> T2)

Oncology ◽  
2002 ◽  
Vol 63 (2) ◽  
pp. 173-179 ◽  
Author(s):  
Wu-Huei Hsu ◽  
Ruoh-Fang Yen ◽  
Chia-Hung Kao ◽  
Shih-Chih Shiun ◽  
Nan-Yung Hsu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Stage Iiib ◽  
Chemotherapy Response ◽  
Cancer Stage ◽  
Small Cell Lung ◽  
T Stage

scholarly journals Prognostic Factors in Advanced Non-Small-Cell Lung Cancer Patients: Patient Characteristics and Type of Chemotherapy

2011 ◽  
Vol 2011 ◽  
pp. 1-4 ◽  
Author(s):  
Salah Abbasi ◽  
Ahmed Badheeb
Keyword(s):  
Lung Cancer ◽  
Prognostic Factors ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Smoking Status ◽  
Performance Status ◽  
Forced Expiratory Volume ◽  
Small Cell ◽  
Chemotherapy Response ◽  
Small Cell Lung

Eleven prognostic factors were retrospectively analyzed in 270 newly diagnosed patients with advanced non-small-cell lung cancer including age, sex, performance status, histology, stage, smoking status, hemoglobin level, forced expiratory volume in one second (FEV1), weight loss >5% in 3 months preceding therapy, number of involved organs, and type of first-line chemotherapy. Response rate was 35.6%, and median survival was 8.2 months (95% CI, 7.8 to 8.7) for the whole group. Age ≤60 years (), (), and the use of platinum/docetaxel () were significantly associated with an improved survival. Histology did not affect outcome in the absence of targeted therapies.

Randomized Phase III Study of Surgery Alone or Surgery Plus Preoperative Cisplatin and Gemcitabine in Stages IB to IIIA Non–Small-Cell Lung Cancer

2012 ◽  
Vol 30 (2) ◽  
pp. 172-178 ◽  
Author(s):  
Giorgio V. Scagliotti ◽  
Ugo Pastorino ◽  
Johan F. Vansteenkiste ◽  
Lorenzo Spaggiari ◽  
Francesco Facciolo ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Radical Surgery ◽  
Small Cell ◽  
Phase Iii ◽  
Disease Stage ◽  
Chemotherapy Response ◽  
Small Cell Lung ◽  
Stage Ib

PurposeThis study aimed to determine whether three preoperative cycles of gemcitabine plus cisplatin followed by radical surgery provides a reduction in the risk of progression compared with surgery alone in patients with stages IB to IIIA non–small-cell lung cancer (NSCLC).Patients and MethodsPatients with chemotherapy-naive NSCLC (stages IB, II, or IIIA) were randomly assigned to receive either three cycles of gemcitabine 1,250 mg/m2days 1 and 8 every 3 weeks plus cisplatin 75 mg/m2day 1 every 3 weeks followed by surgery, or surgery alone. Randomization was stratified by center and disease stage (IB/IIA v IIB/IIIA). The primary end point was progression-free survival (PFS).ResultsThe study was prematurely closed after the random assignment of 270 patients: 129 to chemotherapy plus surgery and 141 to surgery alone. Median age was 61.8 years and 83.3% were male. Slightly more patients in the surgery alone arm had disease stage IB/IIA (55.3% v 48.8%). The chemotherapy response rate was 35.4%. The hazard ratios for PFS and overall survival were 0.70 (95% CI, 0.50 to 0.97; P = .003) and 0.63 (95% CI, 0.43 to 0.92; P = .02), respectively, both in favor of chemotherapy plus surgery. A statistically significant impact of preoperative chemotherapy on outcomes was observed in the stage IIB/IIIA subgroup (3-year PFS rate: 36.1% v 55.4%; P = .002). The most common grade 3 or 4 chemotherapy-related adverse events were neutropenia and thrombocytopenia. No treatment-by-histology interaction effect was apparent.ConclusionAlthough the study was terminated early, preoperative gemcitabine plus cisplatin followed by radical surgery improved survival in patients with clinical stage IIB/IIIA NSCLC.

Sign in / Sign up

Export Citation Format

Share Document